Phase 3 Pancreatic Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are able to understand the study and are willing to sign a written consent form
- People aged 18 to 80 years old
- People whose general physical functioning is rated at a level that allows them to carry out daily activities with little to moderate limitation (confirm with trial site)
- People who have been confirmed through a tissue or cell sample to have pancreatic adenocarcinoma (a specific type of pancreatic cancer) that has spread to other parts of the body
- People whose blood test results show their organs are working well enough to participate
- People who have at least one measurable tumour that can be tracked using standard imaging measurements
- People whose doctors expect them to survive for at least 3 months
- Women who could become pregnant, and men, must be willing to use effective contraception before and throughout the study
Who may not be able to join:
- People who have already received any form of cancer treatment
- People whose biopsy results confirm a type of pancreatic cancer other than adenocarcinoma
- People who have inflammation in the digestive system, such as pancreatitis, cholecystitis, or cholangitis
- Women who are pregnant or currently breastfeeding
- People with serious uncontrolled health conditions that could interfere with the study, such as active serious infections, poorly controlled diabetes, uncontrolled high blood pressure, certain heart conditions, a heart attack in the past 6 months, unstable heart rhythm or chest pain, or a stroke within the past 3 months
- People who have had allergic reactions to gemcitabine, nab-paclitaxel, or similar medicines used in this study
- People with other serious health conditions that the study doctor believes could make treatment unsafe
- People who are unwilling or unable to follow the study procedures
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Guopei Luo, MD, Fudan University
Phone: 86 64175590
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Rate of nausea/vomiting
Can't join this trial?
Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.